GT Biopharma, Inc. (GTBP) — Financial statements
Income statement, balance sheet, and cash flow for GT Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓40.1% | 6↓10.3% | 6↓26.6% | 9↓8.1% | 10 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 48 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑4.5% | 9↑20.5% | 7↓42.9% | 12↓74.0% | 48 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 12↓13.5% | 14↑5.8% | 14↓36.1% | 21↓63.0% | 58 | |
| Total Costs & Expenses | 12↓13.5% | 14↑5.8% | 14↓36.1% | 21↓63.0% | 58 | |
| Operating Results | ||||||
| Operating Income | -12↑13.5% | -14↓5.8% | -14↑36.1% | -21↑63.0% | -58 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 14 | 0.00 | 0.00 | |
| EBITDA | -34↓160.8% | -13↓320.1% | 6↑128.5% | -21↑63.5% | -57 | |
| EBIT | -34↓160.8% | -13↓73.3% | -8↑63.6% | -21↑63.7% | -58 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.00↓101.0% | 0.40↓29.1% | 0.57↑99.6% | 0.28↑141.8% | -0.68 | |
| Interest Income | 0.12↓69.4% | 0.40↓48.5% | 0.78↑167.1% | 0.29↑668.4% | 0.04 | |
| Interest Expense | 0.13 | 0.00↓100.0% | 0.21↑2562.5% | 0.01↓98.9% | 0.72 | |
| Non-Operating Income | 22↑1922.0% | -1↑79.9% | -6↓1469.3% | -0.38↓1774.1% | 0.02 | |
| Other Income / Expenses | -16↓1425.5% | 1↓79.9% | 6↑1502.9% | 0.37↑174.9% | -0.50 | |
| Income Before Tax | -28↓115.4% | -13↓73.3% | -8↑63.6% | -21↑64.0% | -58 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -28↓115.4% | -13↓73.3% | -8↑63.6% | -21↑64.0% | -58 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -28↓115.4% | -13↓73.3% | -8↑63.6% | -21↑64.0% | -58 | |
| Bottom-Line Net Income | -34↓161.7% | -13↓73.3% | -8↑63.6% | -21↑64.0% | -58 | |
| EPS (Basic) | -6.25↑9.9% | -6.94↓23.0% | -5.64↓754.5% | -0.66↑68.0% | -2.06 | |
| EPS (Diluted) | -6.25↑9.9% | -6.94↓23.0% | -5.64↓754.5% | -0.66↑68.0% | -2.06 | |
| Weighted Average Shares | 6↑190.6% | 2↑40.8% | 1↓95.8% | 32↑13.2% | 28 | |
| Weighted Average Diluted Shares | 6↑190.6% | 2↑40.7% | 1↓95.8% | 32↑13.2% | 28 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.